Promedius, a Healthcare AI Startup, Has Secured an $8.4 M in Series A2 Funding.

Promedius(프로메디우스), a healthcare AI startup, has secured $8.4 million (KRW 11.2 billion) in Series A2 funding. This brings the company’s cumulative funding to $10.2 million (KRW 13.6 billion).

Promedius, a healthcare AI startup, has secured an $8.4 million (KRW 11.2 billion) Series A2 round of funding. This brings the company’s cumulative funding to $10.2 million (KRW 13.6 billion).

The Series A2 funding was led by STASSETS Investment, a VC focused on the biohealthcare sector, with new participation from Korea Investment Partners, Woori Venture Partners and CRIT Ventures. The round also included strategic investments from DK Medical, the country’s leading X-ray manufacturer, and Big Move Ventures, the CVC of BUMIN Hospital.

This is the first round of funding since the pivot and reflects the industry’s confidence in Promedius’ innovative direction and growth potential.

Promedius, a spin-off from the Medical Imaging Intelligence Enabling Lab at Asan Medical Center in Seoul, South Korea, is focused on developing and commercialising AI technology that automatically analyses a patient’s risk of osteoporosis using chest x-ray images. The current standard diagnostic method for osteoporosis, dual-energy X-ray absorptiometry (DXA), is a precise way to measure a patient’s bone density, but it is not accessible worldwide. Promedius offers a way to prevent fractures by using easily accessible chest X-rays to screen people at risk of osteoporosis at an early stage, which can lead to timely DXA testing, enabling early diagnosis and treatment to prevent fractures.

“We are excited to advance our AI solutions for the early detection and management of musculoskeletal and metabolic diseases, including osteoporosis, with this Series A2 investment,” said Hyun-Jin Bae, CEO of Promedius. “We will continue to execute on our vision of ‘Delaying Aging through AI’ globally.”